# AI Parkinson's Drug Repurposing 360

## Project System Specification

**Project Version:** 0.1.0  
**Specification Version:** 0.1.0  
**Project Type:** Independent AI/Drug Repurposing Research Project  
**Disease Focus:** Parkinson's Disease (PD)  
**Created:** 2026-10-03 04:07:35  
**Primary Environment:** Google Colab + Google Drive  
**Version Control:** Git / GitHub  

---

# 1. PROJECT PURPOSE

AI Parkinson's Drug Repurposing 360 is an independent, reproducible,
evidence-based computational research framework designed to identify,
evaluate, compare, prioritize, and validate potential drug-repurposing
candidates for Parkinson's disease.

The system will integrate biological, pharmacological, clinical,
translational, safety, biomarker, patient-stratification, and
drug-development evidence.

The final output will be a research-prioritized candidate ranking
supported by traceable evidence.

The system is intended for research prioritization and hypothesis
generation.

It is NOT a clinical decision-support system and must NOT be interpreted
as a recommendation for patients to start, stop, or modify medication.

---

# 2. PRIMARY RESEARCH QUESTION

Can an evidence-integrated AI framework identify and prioritize existing
or previously investigated drugs that have scientifically credible
potential for repurposing in Parkinson's disease?

---

# 3. SECONDARY RESEARCH QUESTIONS

The project will investigate:

1. Which existing drugs have biologically plausible mechanisms relevant
   to Parkinson's disease?

2. Which candidates have evidence of target engagement?

3. Which candidates have preclinical efficacy evidence?

4. Which candidates have human clinical evidence?

5. Which candidates have biomarker evidence?

6. Which candidates have evidence supporting patient stratification?

7. Which candidates have reached Phase I, II, or III clinical testing?

8. Which candidates have failed, partially failed, or produced
   contradictory evidence?

9. What biological deficits or uncertainties explain unresolved
   candidate risk?

10. Which additional experiments would provide the greatest
    information gain?

11. Which candidates should receive the highest research priority based
    on the integrated evidence?

---

# 4. PROJECT SCOPE

The project will evaluate drug-repurposing candidates across multiple
dimensions.

## Core dimensions

- Mechanism of action
- Target biology
- Target validation
- Binding
- Target engagement
- Pharmacology
- CNS relevance
- Blood-brain barrier considerations
- Preclinical efficacy
- Human efficacy
- Clinical trial evidence
- ADMET
- Safety
- Biomarkers
- Patient stratification
- Disease subtype
- Genetic evidence
- Multi-omics evidence
- Clinical development history
- Failure history
- Biology deficits
- Information gain
- Translational feasibility

---

# 5. CANDIDATE DEFINITION

A candidate may include:

- An approved drug
- A previously approved drug
- A drug investigated for another indication
- A drug that has entered human clinical development
- A pharmacologically characterized compound
- A biologically plausible repurposing candidate

Candidates must have sufficient identifiable evidence to permit
structured evaluation.

Candidates with insufficient evidence may be retained as low-confidence
hypotheses but must not be presented as validated candidates.

---

# 6. EVIDENCE HIERARCHY

Evidence will be explicitly classified.

## E0 — No meaningful evidence

No reliable evidence supporting the proposed relationship.

## E1 — Computational evidence

Examples:

- Molecular docking
- Molecular dynamics
- Network pharmacology
- AI predictions
- Machine-learning predictions
- In-silico target prediction

## E2 — Molecular / biochemical evidence

Examples:

- Binding assays
- Enzyme assays
- Target modulation
- Biochemical experiments

## E3 — Cellular evidence

Examples:

- Cell-based assays
- Cellular pathway modulation
- Disease-relevant cellular phenotypes

## E4 — Animal / preclinical evidence

Examples:

- Rodent models
- Non-human animal models
- Behavioral endpoints
- Pharmacodynamic evidence

## E5 — Human observational evidence

Examples:

- Retrospective studies
- Cohort studies
- Epidemiological evidence
- Real-world evidence

## E6 — Human interventional evidence

Examples:

- Randomized controlled trials
- Phase I
- Phase II
- Phase III
- Target-engagement trials

## E7 — Confirmatory clinical evidence

High-quality evidence supporting reproducible clinical benefit,
including appropriately designed confirmatory studies.

Evidence levels must not be treated as interchangeable.

Higher evidence level does not automatically mean that a candidate is
disease-modifying.

---

# 7. PARKINSON'S DISEASE SUBTYPES AND BIOLOGY

Where evidence permits, the framework will distinguish:

- Sporadic Parkinson's disease
- Genetic Parkinson's disease
- GBA1-associated disease
- LRRK2-associated disease
- SNCA-associated disease
- PRKN-associated disease
- PINK1-associated disease
- Other genetically defined subgroups
- Biomarker-defined subgroups
- Mechanistically defined subgroups

Patient stratification must be preserved rather than assuming that
Parkinson's disease is biologically homogeneous.

---

# 8. MECHANISTIC DOMAINS

The framework may evaluate mechanisms involving:

- Dopaminergic signaling
- Alpha-synuclein biology
- Protein aggregation
- Autophagy
- Lysosomal function
- GCase/GBA1 biology
- Mitochondrial dysfunction
- Oxidative stress
- Neuroinflammation
- Neuroimmune signaling
- Neurotrophic signaling
- Synaptic dysfunction
- Calcium homeostasis
- Iron metabolism
- Endosomal trafficking
- Proteostasis
- Metabolic dysfunction
- Genetic risk pathways
- Other validated or emerging mechanisms

Mechanisms must be supported by evidence and should not be inferred solely
from superficial pathway similarity.

---

# 9. CANDIDATE EVALUATION FRAMEWORK

Each candidate should eventually receive a multidimensional evidence
profile.

Proposed dimensions:

1. Target validity
2. Mechanistic plausibility
3. Binding / target engagement
4. Biological efficacy
5. Clinical efficacy
6. CNS exposure / pharmacology
7. ADMET
8. Safety
9. Biomarker availability
10. Patient stratification
11. Clinical evidence
12. Trial history
13. Failure evidence
14. Translational feasibility
15. Biology deficit
16. Information gain
17. Evidence confidence

The exact mathematical scoring system will be specified separately in
RANKING_METHODOLOGY.md.

No final ranking will be generated until the scoring methodology has
been formally defined and validated.

---

# 10. FAILURE ANALYSIS

The system must explicitly capture negative evidence.

Failure categories may include:

- Lack of efficacy
- Safety failure
- Lack of target engagement
- Poor CNS exposure
- Biomarker failure
- Patient-selection failure
- Trial-design limitations
- Dose limitations
- Mechanism failure
- Biological heterogeneity
- Pharmacokinetic limitations
- Pharmacodynamic limitations
- Insufficient statistical power
- Contradictory evidence

Negative evidence must not be discarded merely because it conflicts
with a candidate's mechanistic hypothesis.

---

# 11. BIOLOGY DEFICIT

For each important candidate, the framework should identify unresolved
biological questions.

Examples:

- Target causality uncertain
- Mechanism incompletely established
- Biomarker not validated
- Responder population unknown
- Target engagement uncertain
- Human translational evidence insufficient
- Disease-stage dependency unknown

Biology deficit will become an explicit component of research
prioritization.

---

# 12. INFORMATION GAIN

The framework will estimate which additional experiment, dataset,
biomarker, or clinical study could most reduce uncertainty.

Potential information sources include:

- Target engagement studies
- Biomarker studies
- Genomic studies
- Proteomic studies
- Transcriptomic studies
- Patient stratification studies
- Dose-response studies
- Pharmacokinetic studies
- Pharmacodynamic studies
- Clinical trial data
- Multi-omics integration

Information gain will be used to distinguish "interesting" candidates
from candidates where the next experiment can meaningfully resolve
uncertainty.

---

# 13. RANKING PRINCIPLE

The project will produce a research-priority ranking rather than a
clinical recommendation.

The final ranking must be:

- Evidence-based
- Reproducible
- Traceable
- Auditable
- Version controlled
- Sensitive to contradictory evidence
- Explicit about uncertainty
- Explicit about missing evidence

No candidate will receive a final rank solely because of:

- AI prediction
- Molecular docking
- Literature frequency
- Popularity
- Number of publications
- Commercial interest
- Expert opinion without supporting evidence

---

# 14. AI COMPONENTS

Potential AI components include:

- Large language models
- Retrieval-Augmented Generation (RAG)
- Structured extraction
- Knowledge graphs
- Ontology engineering
- Context engineering
- Prompt engineering
- Agentic workflows
- Evidence classification
- Candidate scoring
- Multi-omics integration
- Literature synthesis
- LLM evaluation

AI-generated claims must be traceable to source evidence whenever
possible.

---

# 15. REPRODUCIBILITY REQUIREMENTS

The project must maintain:

- Versioned code
- Versioned notebooks
- Environment specification
- Package versions
- Configuration files
- Dataset metadata
- Evidence provenance
- Source identifiers
- Retrieval timestamps
- Processing logs
- Validation results
- Model/version information
- Git commit history

The same analysis should be reproducible from documented inputs and
code versions.

---

# 16. DATA GOVERNANCE

Raw datasets will not automatically be committed to GitHub.

The project will use:

- Dataset metadata
- Source URLs or identifiers
- Download instructions
- Checksums where appropriate
- Data dictionaries
- Provenance records
- Licensing information

Sensitive, restricted, copyrighted, or licensed datasets must be
handled according to their applicable terms.

---

# 17. VALIDATION PRINCIPLE

Every major phase must have a validation checkpoint.

A component may only be marked:

COMPLETED

after its required output has been created and validated.

Statuses:

- NOT_STARTED
- IN_PROGRESS
- BLOCKED
- VALIDATION_REQUIRED
- COMPLETED
- FAILED

Dependencies must be explicitly tracked.

---

# 18. PROJECT GOVERNANCE

The following documents will act as controlling project documents:

1. MASTER_CONTROL.md
2. PROJECT_ROADMAP.md
3. NOTEBOOK_REGISTRY.md
4. DATA_DICTIONARY.md
5. EVIDENCE_HIERARCHY.md
6. RANKING_METHODOLOGY.md
7. VALIDATION_PROTOCOL.md
8. CHANGELOG.md

Changes affecting the scientific methodology must be version controlled.

---

# 19. INITIAL PROJECT VERSION

Current project version:

**0.1.0**

Version 0.1.0 represents:

- Project definition
- Initial system architecture
- Initial directory structure
- Initial scientific scope
- Initial reproducibility framework

It does NOT represent a validated drug-repurposing model.

---

# 20. EXPECTED FINAL OUTPUT

The project should ultimately produce:

1. Candidate universe
2. Evidence database
3. Evidence provenance graph
4. Candidate-level evidence profiles
5. Mechanism analysis
6. Clinical trial intelligence
7. Failure analysis
8. Biology deficit analysis
9. Information-gain analysis
10. Reproducible candidate scoring
11. Research-priority ranking
12. Top candidate shortlist
13. Evidence-backed final report
14. Reproducible GitHub repository

---

# 21. SCIENTIFIC BOUNDARY

This project is a computational and translational research framework.

Candidate ranking does not establish:

- Clinical efficacy
- Disease modification
- Regulatory approval
- Individual patient benefit
- Clinical safety for a new indication

Clinical interpretation must remain dependent on appropriate
experimental and clinical evidence.

---

# 22. PROJECT SUCCESS CRITERIA

The project will be considered successful when:

- The complete pipeline is executable.
- Candidate evidence is traceable.
- Evidence levels are explicitly classified.
- Positive and negative evidence are retained.
- Candidate scores are reproducible.
- Validation checks pass.
- Results can be regenerated from version-controlled code.
- The final Top-5 research-priority candidates can be traced back to
  their underlying evidence.

---

# 23. CURRENT STATUS

CODE 1:
PROJECT DIRECTORY STRUCTURE — COMPLETED

CODE 2:
PROJECT CHARTER & SYSTEM SPECIFICATION — IN PROGRESS

Next planned component:

CODE 3 — MASTER CONTROL & DEPENDENCY CHECKLIST

